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This article explores the potential association between co-administration of vancomycin and 
piperacillin-tazobactam with the development of acute kidney injury (AKI) when compared with 
vancomycin and other beta lactam antibiotics or vancomycin monotherapy. Based upon available 
evidence, the combination of vancomycin and piperacillin-tazobactam at therapeutic dosages 
correlates with increased incidence of AKI when compared to vancomycin and cefepime, 
vancomycin and meropenem, and vancomycin monotherapy. The majority of these trials are 
retrospective and most do not evaluate patient outcomes. There remains a need for large, 
prospective, randomized, controlled trials to determine a causative relationship and assess 
clinical ramifications with the concomitant use of vancomycin and piperacillin-tazobactam and 
development of AKI. 
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INTRODUCTION 
 
The combination of antipseudomonal β-
lactams and an agent active against 
methicillin-resistant Staphylococcus aureus 
(MRSA) is often indicated for the empiric 
treatment of severe infections, such as 
diabetic foot infections, sepsis, and the 
treatment of hospital acquired 
pneumonia/ventilator acquired pneumonia. 
An antibiotic regimen that consists of these 
agents provides extensive coverage of both 
Gram-positive and Gram-negative 
organisms. Two of the most commonly 
utilized agents in these situations are 
vancomycin and piperacillin-tazobactam. 
Recently, there has been concern that this 
combination of antimicrobials contributes to 
an elevated risk for development of acute 
kidney injury (AKI). Vancomycin has been 
shown to cause acute tubular necrosis and 
piperacillin-tazobactam has been shown to 
cause acute interstitial nephritis1, but 
determining the true incidence is difficult 
due to the necessity of renal biopsy for 
confirmation of diagnosis2. This article 
seeks to review the reported association 
between co-administration of vancomycin 
and piperacillin-tazobactam and the 
development of AKI. 
 
Description of available literature 
A prospective, open-label, cohort study 
conducted by Peyko et al.
3
 was performed at 
a single medical center over a span of three 
months. It compared the occurrence of AKI 
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in patients receiving vancomycin and 
piperacillin-tazobactam versus vancomycin 
in combination with either cefepime or 
meropenem. The primary outcome of this 
study was the development of AKI 
according to the Kidney Disease: Improving 
Global Outcomes (KDIGO) AKI work-
group criteria4. Patients included in this trial 
had to be greater than 18 years old with an 
order for either piperacillin-tazobactam, 
cefepime, or meropenem for at least 
seventy-two hours and have a steady state 
trough level for vancomycin while receiving 
therapy with a beta lactam. During the 3 
months, 210 patients were identified as 
candidates for the study. Of those patients, 
85 met criteria for inclusion to the study; 59 
were randomized to the vancomycin and 
piperacillin-tazobactam group while 26 were 
randomized to the vancomycin and either 
cefepime or meropenem group. AKI 
developed in 37.3% of the vancomycin and 
piperacillin-tazobactam group compared to 
7.7% of the vancomycin and cefepime or 
meropenem group (p = 0.005), according to 
the KDIGO criteria. Although this study 
demonstrated a correlation of increased AKI 
with vancomycin and piperacillin-
tazobactam, there are notable limitations. 
The sample size in this study was small and 
power was not met, which could limit 
external validity. Patients were not stratified 
according to KDIGO stages, making it 
difficult to quantify the potential impact. 
A meta-analysis performed by 
Giuliano et al.5 analyzed fifteen 
observational studies and assessed the 
incidence of AKI in patients receiving 
vancomycin in combination with 
piperacillin-tazobactam compared to 
vancomycin monotherapy or in combination 
with cefepime or meropenem. Ten of the 
fifteen studies compared vancomycin and 
piperacillin-tazobactam versus vancomycin 
monotherapy. Four of the fifteen studies 
compared vancomycin and piperacillin-
tazobactam to vancomycin and other β-
lactams. Only one study included in the 
analysis compared vancomycin and 
piperacillin-tazobactam with vancomycin 
monotherapy or vancomycin plus other 
antibiotics (mainly cefepime). A total of 
3258 patients comprised the fifteen studies 
that were included in the final analysis. The 
authors found an association with the 
development of AKI and vancomycin and 
piperacillin-tazobactam compared to 
vancomycin alone (OR 3.98; 95% CI 2.749-
5.763; I2 = 31.4%; and p < 0.001). The 
authors performed a secondary analysis that 
removed lesser quality studies and found a 
significantly higher incidence of AKI in 
patients receiving vancomycin and 
piperacillin-tazobactam versus vancomycin 
monotherapy or combined with a different 
β-lactam (OR 4.596; 95% CI 2.929-7.212; I2 
= 0%; p < 0.001). However, when the 
authors compared vancomycin and 
piperacillin/tazobactam versus vancomycin 
and a different beta-lactam (excluding 
vancomycin monotherapy), they found no 
significant difference. Unfortunately, most 
of the data was from trials that compared 
vancomycin monotherapy versus the 
combination of vancomycin and 
piperacillin-tazobactam, leading to potential 
bias with regards to severity of illness. 
Furthermore, a number of the trials included 
in the meta-analysis failed to report 
information such as severity of illness 
scores, vancomycin trough levels, and the 
definition of AKI varied between the trials. 
Despite the limitations of the analysis, the 
results suggest a correlation between 
vancomycin and piperacillin-tazobactam 
combination therapy and AKI incidence. 
Navalkele et al.
6
 performed a 
retrospective, matched, cohort study that 
compared the incidence of AKI in patients 
taking both vancomycin and piperacillin-
tazobactam compared to patients taking 
vancomycin and cefepime. This study 
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defined AKI based on three definitions: the 
RIFLE (Risk, Injury, Failure, Loss, End 
Stage Renal Disease) criteria7, the Acute 
Kidney Injury Network (AKIN) 
classification8, and the Vancomycin 
Consensus Guideline definition9. Patients 
had to have been taking the combination 
antibiotic therapy for greater than forty-eight 
hours in order to be included in this trial. 
Patients were excluded from this trial if they 
had a baseline serum creatinine greater than 
1.2 mg/dL or if they required renal 
replacement therapy at the time combination 
therapy was initiated. There were 329 
patients who received vancomycin and 
piperacillin-tazobactam versus 803 patients 
that received vancomycin and cefepime. Of 
the 803 patients that received vancomycin 
and cefepime, 279 were matched with 
someone from the other treatment group and 
included in the trial. The rate of AKI 
development, based on the RIFLE criteria, 
was greater in the vancomycin and 
piperacillin-tazobactam group (81 patients, 
29%) than the vancomycin and cefepime 
group (31, 11.1%) (HR = 4.0, 95% CI, 2.6-
6.2, p < 0.0001). Per the AKIN criteria 
(stage 1: 48 patients vs. 20 patients, stage 2: 
21 patients vs. 8 patients, and stage 3: 20 
patients vs. 11 patients), rates of AKI were 
higher in the vancomycin and piperacillin-
tazobactam group (32%) than the 
vancomycin and cefepime group (14%) (HR 
3.5; 95% CI, 2.3-5.2; p < 0.0001). And 
finally, per Vancomycin Consensus 
Guidelines, rates of AKIwere also higher in 
the vancomycin and piperacillin-tazobactam 
group versus the vancomycin and cefepime 
group (24% versus 8.2%, respectively) (HR 
4.4; 95% CI, 2.7-7.3; p < 0.0001). The 
median length of stay after initiation of 
combination therapy was longer for 
vancomycin and piperacillin-tazobactam 
patients compared to vancomycin and 
cefepime patients (8 days vs. 6 days; p = 
0.01). There was no significant difference in 
mortality rates between the groups (16 
deaths versus 24 deaths). This trial 
demonstrated that concomitant vancomycin 
and piperacillin-tazobactam correlated with 
a higher incidence of AKI development 
when compared to vancomycin and 
cefepime. The authors should be 
commended for stratifying AKI and utilizing 
different criteria for diagnosis. Additionally, 
the evaluation of mortality and length of 
stay provides insight into the overall impact 
on patient outcomes. 
 
CONCLUSION 
 
Based upon available evidence, the 
combination of vancomycin and 
piperacillin-tazobactam at therapeutic 
dosages has shown a correlation with 
increased incidence of AKI when compared 
to vancomycin and cefepime, vancomycin 
and meropenem, or vancomycin 
monotherapy. However, these trials were not 
without limitations. It is important to note 
the largest study and the studies included in 
the meta-analysis were observational, and 
therefore conclusions should be drawn 
accordingly. 
The results of these studies should 
also be evaluated in the context of their 
varying threshold of AKI categorization. As 
to lend generalizability, future results should 
be stratified for the severity of AKI and 
patient progression to hemodialysis should 
be assessed. Furthermore, due to the low 
threshold of AKI, there may have been 
patients identified as having an AKI that did 
not have clinically significant implications 
on outcomes. 
In current practice, there is a role for 
empiric broad-spectrum antibiotics and the 
use of vancomycin and piperacillin-
tazobactam should not be avoided when 
clinically indicated, especially in patients 
with adequate baseline kidney function. 
Practicing sound stewardship by only using 
 AJHM Volume 1 Issue 3 (Jul-Sept 2017)        REVIEW ARTICLE 
Salvatore et al. www.ajhm.org 4 
 
the combination vancomycin and 
piperacillin-tazobactam when clinically 
indicated could lessen potential harm from 
the combination. Practitioners should 
consider if the expanded anaerobic and 
enterococcal coverage with piperacillin-
tazobactam, when compared to cefepime, is 
warranted. 
It is also important to make health 
care providers aware of this potential 
outcome and consideration should be given 
to patients identified as high risk for kidney 
problems. Furthermore, this correlation 
should be considered when developing a 
hospital formulary, as often the empiric use 
of vancomycin and piperacillin-tazobactam 
is recommended for broad-spectrum 
coverage. 
As a result, there remains a need for 
large, prospective, randomized, controlled 
trials to determine a causative relationship 
and evaluate patient outcomes with the 
concomitant use of vancomycin and 
piperacillin-tazobactam and development of 
AKI. Exploring the additive nephrotoxic 
effects may elucidate the mechanism 
through which vancomycin and piperacillin-
tazobactam interact and lead to better 
identification of at-risk patients. 
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